CORTICOSTEROIDS AND 5ASA VERSUS CORTICOSTEROIDS ALONE FOR ACUTE SEVERE ULCERATIVE COLITIS: A RANDOMIZED CONTROLLED TRIAL. (22nd January 2022)
- Record Type:
- Journal Article
- Title:
- CORTICOSTEROIDS AND 5ASA VERSUS CORTICOSTEROIDS ALONE FOR ACUTE SEVERE ULCERATIVE COLITIS: A RANDOMIZED CONTROLLED TRIAL. (22nd January 2022)
- Main Title:
- CORTICOSTEROIDS AND 5ASA VERSUS CORTICOSTEROIDS ALONE FOR ACUTE SEVERE ULCERATIVE COLITIS: A RANDOMIZED CONTROLLED TRIAL
- Authors:
- Ben-Horin, Shomron
Har-Noy, Ofir
Katsanos, Konstantinos
Roblin, Xavier
Chen, Min-Hu
Gao, Xiang
Schwartz, Doron
Cheon, Jae Hee
Cesarini, Monica
Bojic, Daniela
Protic, Marijana
Theodoropoulou, Angeliki
Abu-Kaf, Heba
Engel, Tal
Tang, Jian
Veyrard, Pauline
Lin, Xiaoqing
Mao, Ren
Christodoulou, Dimitrios
Karmiris, Konstantinos
Knezevic-Ivanovski, Tamara - Abstract:
- Abstract: BACKGROUND: Corticosteroids are the mainstay of treatment for hospitalized patients with acute severe ulcerative colitis (ASUC). However, whether the addition/continuation of 5-aminosalicylates (5ASA) with corticosteroids during hospitalization is superior to corticosteroids alone is unknown METHODS: This was a randomized controlled investigator-blinded clinical trial conducted in ten centers in six countries. Patients hospitalized with ASUC (Lichtiger score ≥10) were eligible. Patients received corticosteroids alone or corticosteroid+5ASA (4gr/day mesalamine) by a stratified randomization according to 5ASA use prior to admission. The primary outcome was the percentage of patients who responded to treatment by day 7, defined by a drop>3 points in the Lichtiger score and an absolute score<10 without the need for rescue medications or colectomy. RESULTS: 346 patients were screened and 149 were included (70/149 females, median age 41). Of these, 73 received corticosteriods+5ASA and 76 corticosteroids alone. For the primary outcome, 53/73 (72.6%) of patients receiving corticosteroids with 5ASA responded versus 58/76 (76.3%) of patients on corticosteroids alone (OR 0.82 95%CI 0.39-1.72, p=0.60). There was no difference between groups in duration of hospitalization or CRP normalization rate. Colectomy rate up to day 90 was similar, but the need for biologics among patients receiving combination corticosteroids with 5ASA was numerically lower by day 30 (p=0.11) and day 90Abstract: BACKGROUND: Corticosteroids are the mainstay of treatment for hospitalized patients with acute severe ulcerative colitis (ASUC). However, whether the addition/continuation of 5-aminosalicylates (5ASA) with corticosteroids during hospitalization is superior to corticosteroids alone is unknown METHODS: This was a randomized controlled investigator-blinded clinical trial conducted in ten centers in six countries. Patients hospitalized with ASUC (Lichtiger score ≥10) were eligible. Patients received corticosteroids alone or corticosteroid+5ASA (4gr/day mesalamine) by a stratified randomization according to 5ASA use prior to admission. The primary outcome was the percentage of patients who responded to treatment by day 7, defined by a drop>3 points in the Lichtiger score and an absolute score<10 without the need for rescue medications or colectomy. RESULTS: 346 patients were screened and 149 were included (70/149 females, median age 41). Of these, 73 received corticosteriods+5ASA and 76 corticosteroids alone. For the primary outcome, 53/73 (72.6%) of patients receiving corticosteroids with 5ASA responded versus 58/76 (76.3%) of patients on corticosteroids alone (OR 0.82 95%CI 0.39-1.72, p=0.60). There was no difference between groups in duration of hospitalization or CRP normalization rate. Colectomy rate up to day 90 was similar, but the need for biologics among patients receiving combination corticosteroids with 5ASA was numerically lower by day 30 (p=0.11) and day 90 (p=0.07). CONCLUSION: In this randomized controlled trial, combination 5ASA with corticosteroids did not benefit hospitalized patients with ASUC more than corticosteroids alone. An exploratory finding of a reduced need for biologics at 90 days in the combination group merits further evaluation. … (more)
- Is Part Of:
- Inflammatory bowel diseases. Volume 28(2022)Supplement 1
- Journal:
- Inflammatory bowel diseases
- Issue:
- Volume 28(2022)Supplement 1
- Issue Display:
- Volume 28, Issue 1 (2022)
- Year:
- 2022
- Volume:
- 28
- Issue:
- 1
- Issue Sort Value:
- 2022-0028-0001-0000
- Page Start:
- S14
- Page End:
- S14
- Publication Date:
- 2022-01-22
- Subjects:
- Inflammatory bowel diseases -- Periodicals
Colitis, Ulcerative -- Periodicals
Crohn Disease -- Periodicals
Inflammatory Bowel Diseases -- Periodicals
616.344 - Journal URLs:
- http://journals.lww.com/ibdjournal/pages/default.aspx ↗
http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1536-4844/ ↗
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=toc&D=ovft&AN=00054725-000000000-00000 ↗
https://academic.oup.com/ibdjournal ↗
http://journals.lww.com ↗ - DOI:
- 10.1093/ibd/izac015.021 ↗
- Languages:
- English
- ISSNs:
- 1078-0998
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4478.845400
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 20910.xml